{"transactions":[{"id":1182392,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President ,CEO & CMO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T09:06:50.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":918308,"price":0.98,"value":899941.84,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31,2025 and the remainder vesting in 36 equal monthly instalments thereafter subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":918308,"derivative":{"exercise_price":0.98,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":918308},"source":{"system":"sec-edgar","filing":"0000950170-25-048905","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000095017025048905/ownership.xml","form_type":"4"}},{"id":1322532,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-23T16:33:32.000Z","date":"2024-12-23","kind":"grant","planned":false,"acquired":true,"shares":1135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date."}],"balance_after":1135000,"derivative":{"exercise_price":1.67,"expiration_date":"2034-12-23","underlying":"Common Stock","underlying_shares":1135000},"source":{"system":"sec-edgar","filing":"0000950170-24-139616","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000095017024139616/ownership.xml","form_type":"4"}},{"id":1558176,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-28T16:33:30.000Z","date":"2024-03-26","kind":"grant","planned":false,"acquired":true,"shares":1071242,"price":3.83,"value":4102856.86,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 26, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":1071242,"derivative":{"exercise_price":3.83,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":1071242},"source":{"system":"sec-edgar","filing":"0000950170-24-038106","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000095017024038106/ownership.xml","form_type":"4"}},{"id":1778603,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-18T19:03:40.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":8541,"price":2.1,"value":17936.1,"ownership":{"direct":true},"balance_after":2403882,"source":{"system":"sec-edgar","filing":"0001209191-23-049826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049826/doc4.xml","form_type":"4"}},{"id":1778602,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-18T19:03:40.000Z","date":"2023-09-14","kind":"sale","planned":false,"acquired":false,"shares":100,"price":2.25,"value":225.0,"ownership":{"direct":true},"balance_after":2412423,"source":{"system":"sec-edgar","filing":"0001209191-23-049826","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049826/doc4.xml","form_type":"4"}},{"id":1781705,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:16:19.000Z","date":"2023-09-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":184742,"price":2.13,"value":393500.46,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units."}],"balance_after":2412523,"source":{"system":"sec-edgar","filing":"0001209191-23-049366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049366/doc4.xml","form_type":"4"}},{"id":1781704,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:16:19.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":3000,"price":2.2719,"value":6815.7,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades in prices ranging from $2.25 to $2.34."}],"balance_after":2597265,"source":{"system":"sec-edgar","filing":"0001209191-23-049366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049366/doc4.xml","form_type":"4"}},{"id":1781703,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:16:19.000Z","date":"2023-09-12","kind":"sale","planned":false,"acquired":false,"shares":4917,"price":2.2516,"value":11071.1172,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $2.21 to $2.30."}],"balance_after":2600265,"source":{"system":"sec-edgar","filing":"0001209191-23-049366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049366/doc4.xml","form_type":"4"}},{"id":1781702,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-13T20:16:19.000Z","date":"2023-09-11","kind":"sale","planned":false,"acquired":false,"shares":20000,"price":2.2707,"value":45414.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $2.13 to $2.36."}],"balance_after":2605182,"source":{"system":"sec-edgar","filing":"0001209191-23-049366","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123049366/doc4.xml","form_type":"4"}},{"id":1784427,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-08T17:00:23.000Z","date":"2023-09-07","kind":"grant","planned":false,"acquired":true,"shares":469483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that are fully vested."}],"balance_after":2625182,"source":{"system":"sec-edgar","filing":"0001209191-23-048814","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123048814/doc4.xml","form_type":"4"}},{"id":1936450,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":61825,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":61825,"derivative":{"exercise_price":2.21,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":61825},"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1936449,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":990461,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":990461,"derivative":{"exercise_price":2.21,"expiration_date":"2031-03-30","underlying":"Common Stock","underlying_shares":990461},"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1936448,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":61825,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":8.71,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":61825},"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1936447,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":990461,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the \"Plan\"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These stock options vest in 48 substantially-equal monthly installments beginning January 2, 2020, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":5.34,"expiration_date":"2031-03-30","underlying":"Common Stock","underlying_shares":990461},"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":1936446,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-28T16:48:11.000Z","date":"2023-03-24","kind":"grant","planned":false,"acquired":true,"shares":703379,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":2155699,"source":{"system":"sec-edgar","filing":"0001209191-23-021415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000120919123021415/doc4.xml","form_type":"4"}},{"id":2071995,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-03T19:39:07.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":95684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date."}],"balance_after":1452320,"source":{"system":"sec-edgar","filing":"0001567619-23-000068","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000156761923000068/doc1.xml","form_type":"4"}},{"id":2296158,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-15T19:56:52.000Z","date":"2022-04-14","kind":"grant","acquired":true,"shares":315273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 95,684 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Compensation Committee also approved a grant to the Reporting Person of $200,000 cash compensation that is payable in full on April 13, 2023, subject to the Reporting Person's continued employment through the payment date."}],"balance_after":1356636,"source":{"system":"sec-edgar","filing":"0001567619-22-008613","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000156761922008613/doc1.xml","form_type":"4"}},{"id":2307016,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-04-04T16:15:53.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":742574,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":1041363,"source":{"system":"sec-edgar","filing":"0001140361-22-012924","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000114036122012924/form4.xml","form_type":"4"}},{"id":2544082,"issuer":{"id":5986,"kind":"organization","name":"Pyxis Oncology, Inc.","symbol":"PYXS"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2021-10-12T19:47:31.000Z","date":"2021-10-07","kind":"grant","acquired":true,"shares":962289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Two-thirds of these stock options vest 25% on the first anniversary of the October 7, 2021 grant date, and then in 36 substantially-equal monthly installments thereafter, and one-third of these stock options vest in full on the fourth anniversary of the October 7, 2021 grant date, all subject to the reporting person's continued employment through the applicable vesting date."}],"balance_after":962289,"derivative":{"exercise_price":16,"expiration_date":"2031-10-07","underlying":"Common Stock","underlying_shares":962289},"source":{"system":"sec-edgar","filing":"0001140361-21-034421","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1769457/000114036121034421/form4.xml","form_type":"4"}},{"id":3496907,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2019-06-07T20:17:03.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":3537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3537,"derivative":{"exercise_price":5.23,"exercise_date":"2020-06-06","expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":3537},"source":{"system":"sec-edgar","filing":"0001140361-19-010673","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036119010673/form4.xml","form_type":"4"}},{"id":3622906,"issuer":{"id":5892,"kind":"organization","name":"Opus Genetics, Inc.","symbol":"IRD"},"owners":[{"id":81202,"kind":"person","name":"Sullivan Lara","position":1,"cik":"0001769457","reported_name":"Sullivan Lara","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2019-03-01T22:31:33.000Z","date":"2019-02-27","kind":"grant","acquired":true,"shares":84968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options will vest and become exercisable based on the following schedule: 28,322 on February 27, 2020, 28,323 on  February 27, 2021, and 28,323 on February 27, 2022."}],"balance_after":84968,"derivative":{"exercise_price":0.53,"expiration_date":"2019-02-27","underlying":"Common Stock","underlying_shares":84968},"source":{"system":"sec-edgar","filing":"0001140361-19-004271","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036119004271/form4.xml","form_type":"4"}}]}